| Overall symptom severity in IBS with diarrhea — Bif195 | No significant advantage was found on the overall IBS symptom scale. Scores changed by −43.3 versus −38.2 points. The small sample does not rule out an effect. | 2/4 LowPrecision of the estimate. Small sample, lack of a confidence interval, or a substantial number of missing outcomes. Consistency across studies. Different strains and products do not independently replicate the same result. Inconsistency cannot be assessed for this specific combination of participants, intervention, comparator, and outcome. The original assessment applied no additional downgrade on this basis (0 levels). Applicability to the specified group. Direct evidence for the specified participants, strain, and outcome. Potential publication bias. There are too few direct studies to assess publication bias. The original assessment applied no additional downgrade on this basis (0 levels). Risk of bias. One small randomized study. Uncertainties about group allocation and reporting, along with missing outcomes, reduce confidence. | 11 publication describedEight weeks of treatment with probiotic Bifidobacterium breve, Bif195 lowers fatigue scores in patients with diarrhoea-predominant irritable bowel syndrome: results from a randomised, clinical trial ↗ | 61 adults with diarrhea-predominant IBS, 52 included in the analysis | - Eight weeks of treatment with probiotic Bifidobacterium breve, Bif195 lowers fatigue scores in patients with diarrhoea-predominant irritable bowel syndrome: results from a randomised, clinical trial ↗
|
|---|
| Antibiotic-associated diarrhea in children — PRL2020 | Diarrhea was reported in 6/71 versus 14/50 participants who completed the study. In the control group, 21 of 71 participants dropped out, so the true magnitude of the effect is highly uncertain. | 1/4 Very lowPrecision of the estimate. Small sample, lack of a confidence interval, or a substantial number of missing outcomes. Consistency across studies. Different strains and products do not independently replicate the same result. Inconsistency cannot be assessed for this specific combination of participants, intervention, comparator, and outcome. The original assessment applied no additional downgrade on this basis (0 levels). Applicability to the specified group. Direct evidence for the specified participants, strain, and outcome. Potential publication bias. There are too few direct studies to assess publication bias. The original assessment applied no additional downgrade on this basis (0 levels). Risk of bias. The outcome was assessed without blinding, and attrition was very uneven between groups after randomization. The missing results could substantially change the direction of the effect. | 11 publication describedBifidobacterium breve PRL2020 mitigates antibiotic-induced gut symptoms and dysbiosis in children treated with amoxicillin or amoxicillin-clavulanate ↗ | 142 children aged 3–12 taking amoxicillin or amoxicillin with clavulanate, 121 completed the study | - Bifidobacterium breve PRL2020 mitigates antibiotic-induced gut symptoms and dysbiosis in children treated with amoxicillin or amoxicillin-clavulanate ↗
|
|---|
| Cognitive tests in people with suspected mild impairment — MCC1274/A1 | At week 16, the adjusted RBANS total cognitive test score was 11.3 points higher than with placebo (95% confidence interval 6.7–15.8). This finding concerns adults with suspected mild cognitive impairment. | 2/4 LowPrecision of the estimate. One study with 80 participants. The confidence interval of 6.7–15.8 RBANS points allows for substantially different magnitudes of improvement. Independent replication is limited. Consistency across studies. Different strains and products do not independently replicate the same result. Inconsistency cannot be assessed for this specific combination of participants, intervention, comparator, and outcome. The original assessment applied no additional downgrade on this basis (0 levels). Applicability to the specified group. The stated target group is people with suspected mild cognitive impairment. The conclusion does not extend to healthy people or dementia prevention. Potential publication bias. There are too few direct studies to assess publication bias. The original assessment applied no additional downgrade on this basis (0 levels). Risk of bias. There is uncertainty about the reporting of this particular study and the relevance of the result to everyday functioning. The data pertain to a group with impairments. | 11 publication describedProbiotic Bifidobacterium breve in Improving Cognitive Functions of Older Adults with Suspected Mild Cognitive Impairment: A Randomized, Double-Blind, Placebo-Controlled Trial ↗ | 80 adults aged 50–79 with suspected mild cognitive impairment, 79 completed the study | - Probiotic Bifidobacterium breve in Improving Cognitive Functions of Older Adults with Suspected Mild Cognitive Impairment: A Randomized, Double-Blind, Placebo-Controlled Trial ↗
|
|---|
| Subjective sleep quality — CCFM1025 | Over 4 weeks, the mean Pittsburgh Sleep Quality Index (PSQI) score decreased by 3.85 points with CCFM1025 and by 1.45 points with placebo. The simple difference in changes was −2.40 points. | 1/4 Very lowPrecision of the estimate: A small sample or the absence of a confidence interval leaves uncertainty. Consistency across studies: Inconsistency in results for this specific strain and outcome has not been established. The original assessment applied no additional downgrade on this basis (0 levels). Applicability to the specified group: The result applies only to the specified strain, dose, participants, and outcome. Possible publication bias: There are too few studies to assess publication bias, and there is no direct evidence of missing studies. The original assessment applied no additional downgrade on this basis (0 levels). Risk of bias: The study has noted limitations involving participant selection, reporting, or missing data. | 11 publication describedBifidobacterium breve CCFM1025 Improves Sleep Quality via Regulating the Activity of the HPA Axis: A Randomized Clinical Trial ↗ | 40 adults aged 18–65 with stress-related insomnia and a baseline PSQI score above 7 | - Bifidobacterium breve CCFM1025 Improves Sleep Quality via Regulating the Activity of the HPA Axis: A Randomized Clinical Trial ↗
|
|---|
| Fat mass in the first trial — B-3 | Over 12 weeks, the change in fat mass differed between groups by about 0.6 kg in favor of B-3 (p=0.03 after adjustment for baseline values). The graph shows that fat mass stayed near baseline with B-3 and increased with placebo. | 2/4 LowPrecision of the estimate: A small sample or the absence of a confidence interval leaves uncertainty. Consistency across studies: Inconsistency in results for this specific strain and outcome has not been established. The original assessment applied no additional downgrade on this basis (0 levels). Applicability to the specified group: The result applies only to the specified strain, dose, participants, and outcome. Possible publication bias: There are too few studies to assess publication bias, and there is no direct evidence of missing studies. The original assessment applied no additional downgrade on this basis (0 levels). Risk of bias: The study has noted limitations involving participant selection, reporting, or missing data. | 11 publication describedEffects of Bifidobacterium breve B-3 on body fat reductions in pre-obese adults: a randomized, double-blind, placebo-controlled trial ↗ | 80 adults with a BMI of 25–30, predominantly men | - Effects of Bifidobacterium breve B-3 on body fat reductions in pre-obese adults: a randomized, double-blind, placebo-controlled trial ↗
|
|---|
| DXA-measured fat mass in the second trial — B-3 | In another study, fat mass changed by −587 g versus −64 g, with an adjusted difference of about −529 g. | 2/4 LowPrecision of the estimate: A small sample or the absence of a confidence interval leaves uncertainty. Consistency across studies: Inconsistency in results for this specific strain and outcome has not been established. The original assessment applied no additional downgrade on this basis (0 levels). Applicability to the specified group: The result applies only to the specified strain, dose, participants, and outcome. Possible publication bias: There are too few studies to assess publication bias, and there is no direct evidence of missing studies. The original assessment applied no additional downgrade on this basis (0 levels). Risk of bias: The study has noted limitations involving participant selection, reporting, or missing data. | 11 publication describedBody Fat Reduction Effect of Bifidobacterium breve B-3: A Randomized, Double-Blind, Placebo Comparative Clinical Trial ↗ | 83 adults with elevated fat mass in the per-protocol analysis | - Body Fat Reduction Effect of Bifidobacterium breve B-3: A Randomized, Double-Blind, Placebo Comparative Clinical Trial ↗
|
|---|
| Total body weight — B-3 | In the 2022 study, the authors reported that by week 12, total body weight was lower in the B-3 group than in the placebo group. The exact difference in weight could not be confirmed from the available data. | 2/4 LowPrecision of the estimate: A small sample or the absence of a confidence interval leaves uncertainty. Consistency across studies: Inconsistency in results for this specific strain and outcome has not been established. The original assessment applied no additional downgrade on this basis (0 levels). Applicability to the specified group: The result applies only to the specified strain, dose, participants, and outcome. Possible publication bias: There are too few studies to assess publication bias, and there is no direct evidence of missing studies. The original assessment applied no additional downgrade on this basis (0 levels). Risk of bias: The study has noted limitations involving participant selection, reporting, or missing data. | 11 publication describedBody Fat Reduction Effect of Bifidobacterium breve B-3: A Randomized, Double-Blind, Placebo Comparative Clinical Trial ↗ | Adults with elevated fat mass in the 2022 B-3 trial | - Body Fat Reduction Effect of Bifidobacterium breve B-3: A Randomized, Double-Blind, Placebo Comparative Clinical Trial ↗
|
|---|
| Knee extension strength in sarcopenia — inactivated B-3 | After 24 weeks, the between-group difference in the change in knee extension strength was +0.55 kgf (95% confidence interval −1.10 to +2.10 kgf, p=0.554). No statistically significant benefit was found. | 2/4 LowPrecision of the estimate. Small sample, lack of a confidence interval, or a substantial number of missing outcomes. Consistency across studies. Different strains and products do not independently replicate the same result. Inconsistency cannot be assessed for this specific combination of participants, intervention, comparator, and outcome. The original assessment applied no additional downgrade on this basis (0 levels). Applicability to the specified group. Direct evidence for the specified participants, strain, and outcome. Potential publication bias. There are too few direct studies to assess publication bias. The original assessment applied no additional downgrade on this basis (0 levels). Risk of bias. One small randomized study. Uncertainties about group allocation and reporting, along with missing outcomes, reduce confidence. | 11 publication describedEffects of Heat-Killed Bifidobacterium breve B-3, a Postbiotic, on Muscle Mass-Related Parameters in Patients with Sarcopenia: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial ↗ | 50 adults aged 50–89 years with sarcopenia were enrolled, and 49 were included in the analysis. By week 24, strength data were available for 43 participants. | - Effects of Heat-Killed Bifidobacterium breve B-3, a Postbiotic, on Muscle Mass-Related Parameters in Patients with Sarcopenia: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial ↗
|
|---|
| Brown skin spots assessed by imaging — M-16V | Image analysis showed that the median change in the brown spot score was −1.00 versus −0.05 at week 4 (p=0.013) and −0.50 versus −0.06 at week 8 (p=0.041). Whether the difference was noticeable in everyday life was not assessed. | 2/4 LowPrecision of the estimate: A small sample or the absence of a confidence interval leaves uncertainty. Consistency across studies: Inconsistency in results for this specific strain and outcome has not been established. The original assessment applied no additional downgrade on this basis (0 levels). Applicability to the specified group: The result applies only to the specified strain, dose, participants, and outcome. Possible publication bias: There are too few studies to assess publication bias, and there is no direct evidence of missing studies. The original assessment applied no additional downgrade on this basis (0 levels). Risk of bias: The study has noted limitations involving participant selection, reporting, or missing data. | 11 publication describedImaging and Microorganism Analyses of the Effects of Oral Bifidobacterium breve Intake on Facial Skin in Females: A Randomized, Double-Blind, Placebo-Controlled Study ↗ | 120 Japanese women aged 30–79 | - Imaging and Microorganism Analyses of the Effects of Oral Bifidobacterium breve Intake on Facial Skin in Females: A Randomized, Double-Blind, Placebo-Controlled Study ↗
|
|---|
| Overall skin score assessed by imaging — M-16V | Worsening within the placebo group alone does not establish an improvement in the primary VISIA measure. The abstract did not establish a between-group benefit. | 2/4 LowPrecision of the estimate: A small sample or the absence of a confidence interval leaves uncertainty. Consistency across studies: Inconsistency in results for this specific strain and outcome has not been established. The original assessment applied no additional downgrade on this basis (0 levels). Applicability to the specified group: The result applies only to the specified strain, dose, participants, and outcome. Possible publication bias: There are too few studies to assess publication bias, and there is no direct evidence of missing studies. The original assessment applied no additional downgrade on this basis (0 levels). Risk of bias: The study has noted limitations involving participant selection, reporting, or missing data. | 11 publication describedImaging and Microorganism Analyses of the Effects of Oral Bifidobacterium breve Intake on Facial Skin in Females: A Randomized, Double-Blind, Placebo-Controlled Study ↗ | 120 Japanese women aged 30–79 | - Imaging and Microorganism Analyses of the Effects of Oral Bifidobacterium breve Intake on Facial Skin in Females: A Randomized, Double-Blind, Placebo-Controlled Study ↗
|
|---|
| Self-rated skin condition — M-16V | Self-reported measures of skin condition improved in both groups, with no statistically significant difference between them. | 2/4 LowPrecision of the estimate. Small sample, lack of a confidence interval, or a substantial number of missing outcomes. Consistency across studies. Different strains and products do not independently replicate the same result. Inconsistency cannot be assessed for this specific combination of participants, intervention, comparator, and outcome. The original assessment applied no additional downgrade on this basis (0 levels). Applicability to the specified group. Direct evidence for the specified participants, strain, and outcome. Potential publication bias. There are too few direct studies to assess publication bias. The original assessment applied no additional downgrade on this basis (0 levels). Risk of bias. One small randomized study. Uncertainties about group allocation and reporting, along with missing outcomes, reduce confidence. | 11 publication describedImaging and Microorganism Analyses of the Effects of Oral Bifidobacterium breve Intake on Facial Skin in Females: A Randomized, Double-Blind, Placebo-Controlled Study ↗ | 120 healthy women aged 30–79 | - Imaging and Microorganism Analyses of the Effects of Oral Bifidobacterium breve Intake on Facial Skin in Females: A Randomized, Double-Blind, Placebo-Controlled Study ↗
|
|---|